Table 2.
Hematological and renal response to eculizumab therapy in 15 cTMA patients
| Characteristic | Baseline | 4 weeks | 6 months | Last FU |
|---|---|---|---|---|
| Anemia | 14 (93.3%) | 13 (86.7%) | 11 (84.6%) | 7 (46.6%) |
| Mean Hb (g/dL) | 8.5 (± 2.7) | 10.5 (± 1.7) | 11 (± 2) | 12.2 (± 1.5) |
| Thrombopenia | 10 (66.7%) | 2 (13.3%) | 1 (7.7%) | 1 (8.3%) |
| Mean PLT count (G/L) | 145 (± 131) | 240 (± 135) | 253 (± 74) | 246 (± 65) |
| Mean LDH (U/L) | 552 (± 436) | 301 (± 105) | 192 (± 41) | 181 (± 33) |
| AKI | 12 (80%) | n.a | n.a | n.a |
| RRT | 6 (40%) | 3 (20%) | 2 (14.3%) | 1 (7.7%) |
| Mean SCr (mg/dL) | 3.3 (± 2.6) | 2.67 (± 1.88) | 1.73 (± 0.79) | 2.06 (± 1.49) |
| Mean PKR (mg/g) | 1,872 (± 2,391) | 1,505 (± 1,907) | 947 (± 1,155) | 851 (± 998) |
| KTX | 4 (26.7%) | 4 (26.7%) | 4 (26.7%) | 5 (33.3%) |
| Patients on Ecu therapy | 15 (100%) | 15 (100%) | 11 (67%) | 5 (33.3%) |
| Lost to FU | 0 | 2 (13.3%) | 2 (13.3%) | 3 (20%) |
Numbers are count and percent or mean and standard deviation. No 4 week + 6mo FU data for 2 (only lab results). No last FU lab data for 3 pat. Anemia was defined as Hb levels of < 12.5 g/dL for female and < 13.5 g/dL for male patients. Thrombopenia was defined as platelet count < 150 G/L
cTMA complement gene-variant mediated thrombotic microangiopathy, FU follow-up, Hb hemoglobin, PLT platelets, LDH lactate dehydrogenase, SCr serum creatinine, PKR protein-creatinine ratio, RRT renal replacement therapy, KTX kidney transplantation, Ecu eculizumab